Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK2 | O95069 | 1/20 | 0.61 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.61 |
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 6/20 | 0.42 |
| ▸ | DRD2 | P14416 | 5/20 | 0.42 |
| ▸ | HTR7 | P34969 | 5/20 | 0.42 |
| ▸ | HTR2A | P28223 | 4/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5070744 | 0.93 | KCNK2 (0.54) | KCNK2SCN2AHRH4HTR3AKMT2A | |
| SCHEMBL8842601 | 0.86 | PIK3CA (0.46) | KCNK2SCN2A | |
| SCHEMBL7277240 | 0.85 | SCN2A (0.44) | KCNK2SCN2AHRH4HTR3A | |
| SCHEMBL7273354 | 0.83 | HRH4 (0.50) | KCNK2SCN2AHRH4HTR3AKMT2A | |
| SCHEMBL134764 | 0.83 | KCNK2 (0.67) | KCNK2SCN2AHRH4HTR3AKMT2A | |
| Sipatrigine SCHEMBL135888 | 0.76 | SCN2A (1.00) | KCNK2SCN2AHRH4HTR3AKMT2A | |
| Sipatrigine SCHEMBL29421474 | 0.76 | SCN2A (1.00) | KCNK2SCN2AHRH4HTR3AKMT2A | |
| SCHEMBL170312 | 0.76 | SCN2A (0.43) | KCNK2SCN2AKMT2AHTR2AHTR1A | |
| SCHEMBL7382696 | 0.75 | KCNK2 (0.61) | KCNK2SCN2AHRH4HTR3AHTR6 | |
| SCHEMBL6049502 | 0.73 | SCN2A (0.39) | KCNK2SCN2AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0727213-B9 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | WELLCOME FOUND (GB) | 2007-11-07 | — | — | EP | claimed |
| EP-0727213-B1 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | WELLCOME FOUND (GB) | 2005-10-26 | — | — | EP | claimed |
| US-20040229873-A1 | Treatment of neurodegenerative conditions | BTG INTERNATIONAL LIMITED (GB) | 2004-11-18 | — | — | US | claimed |
| US-5712276-A | TREATING NERVOUS SYSTEM DISORDERS | GLAXO WELLCOME INC. (US) | 1998-01-27 | — | — | US | claimed |
| US-5684005-A | PHENYLPYRIMIDINE COMPOUNDS AS INHIBITORS OF EXCITATORY AMINO ACID GLUTAMATE | GLAXO WELLCOME INC. (US) | 1997-11-04 | — | — | US | claimed |
| EP-0372934-A2 | Pharmacologically active CNS compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-06-13 | — | — | EP | claimed |
| US-20140079757-A1 | ORAL DRUG DELIVERY FORMULATIONS | BROWN RUDNICK LLP | 2014-03-20 | — | — | US | disclosed |
| WO-2012028963-A2 | COMPOSITIONS INCLUDING A SODIUM CHANNEL BLOCKER AND A B VITAMIN MOLECULE AND METHODS OF USE THEREOF | MS THERAPEUTICS LIMITED (GB) | 2012-03-08 | — | — | WO | disclosed |
| US-20120058097-A1 | COMPOSITIONS INCLUDING A SODIUM CHANNEL BLOCKER AND A B VITAMIN MOLECULE AND METHODS OF USE THEREOF | MS THERAPEUTICS LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| EP-1325916-B1 | Piperazinyl-substituted phenyl pyrimidine derivatives useful in the treatment or prevention of disorders of the central nervous system | WELLCOME FOUND (GB) | 2008-01-23 | — | — | EP | disclosed |
| EP-0727213-B9 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | WELLCOME FOUND (GB) | 2007-11-07 | — | — | EP | disclosed |
| EP-1681058-A2 | Pharmacologically active cns compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 2006-07-19 | — | — | EP | disclosed |
| EP-0727213-B1 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | WELLCOME FOUND (GB) | 2005-10-26 | — | — | EP | disclosed |
| CN-1119099-A | Method for preparing pharmacologically active CNS composition | WELLCOME FOUND (GB) | 1996-03-27 | — | — | CN | disclosed |
| CN-1117046-A | Method for preparing pharmaceutically active CNS compounds | WELLCOME FOUND (GB) | 1996-02-21 | — | — | CN | disclosed |
| CN-1115756-A | Method for preparing pharmaceutically active CNS compounds | WELLCOME FOUND (GB) | 1996-01-31 | — | — | CN | disclosed |
| EP-0679645-A1 | Pharmacologically active CNS pyridmidin compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-11-02 | — | — | EP | disclosed |
| US-5136080-A | Intermediates for glutamate inhibitors | BURROUGHS WELLCOME CO. (US) | 1992-08-04 | — | — | US | disclosed |
| EP-0459819-A2 | Pharmacologically active CNS compound | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-12-04 | — | — | EP | disclosed |
| EP-0372934-A2 | Pharmacologically active CNS compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058097-A1 | COMPOSITIONS INCLUDING A SODIUM CHANNEL BLOCKER AND A B VITAMIN MOLECULE AND METHODS OF USE THEREOF | CACNA1B, KCNMB1, KCNB2 | KCNK2 103/4885SCN2A 25/4885HRH4 3061/4885 |
| US-20040229873-A1 | Treatment of neurodegenerative conditions | CHRM2, CHRNA3, CHRNA2 | KCNK2 136/4885SCN2A 63/4885HRH4 58/4885 |
| US-20140079757-A1 | ORAL DRUG DELIVERY FORMULATIONS | PGF, MMP1, MMP26 | KCNK2 3641/4885SCN2A 4830/4885HRH4 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.